{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:25:02Z","timestamp":1771511102931,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":10020,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1985,10]]},"abstract":"<jats:p>Studies of digitalis have revealed an appreciable role of the autonomic nervous system in the modulation of the cardiovascular toxicity of digitalis. Neuraxis transection experiments and studies using digitalis compounds that fail to enter the central nervous system suggest that centers located in the floor of the fourth cerebral ventricle play a substantial part in the neural arrhythmogenic effects of the digitalis glycosides. Electrical stimulation of the area postrema in partially digitalized animals, not otherwise manifesting ventricular arrhythmias, elicits ventricular tachycardia. Neuraxis transection experiments and studies with a charged digitalis derivative also suggest localization of the coronary vasoconstrictive properties of digitalis to the area postrema. The results suggest that this region of the brainstem is sensitive to a neurally active substance, digitalis, causing peripheral sympathetic effects of considerable consequence.<\/jats:p>","DOI":"10.1177\/009127008502500709","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T00:52:18Z","timestamp":1182473538000},"page":"529-539","source":"Crossref","is-referenced-by-count":11,"title":["Digitalis: Neurally Mediated Arrhythmogenic and Coronary Vasoconstrictor Properties"],"prefix":"10.1002","volume":"25","author":[{"given":"John Charin","family":"Somberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"227","article-title":"The nervous system as a site of action of digitalis and antiarrhythmic drugs","volume":"37","author":"Levitt B","year":"1970","journal-title":"Mt Sinai J Med"},{"key":"e_1_2_1_3_2","first-page":"19","article-title":"The role of the nervous system in cardiovascular effects of digitalis","volume":"31","author":"Gillis R","year":"1979","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(76)90435-5"},{"key":"e_1_2_1_5_2","first-page":"24","article-title":"Alteration of the effects and distribution of ouabain by spinal cord transection in the cat","volume":"185","author":"Levitt B","year":"1973","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/10.4.487"},{"key":"e_1_2_1_7_2","first-page":"263","article-title":"Centrally mediated protective effects of dopamine agonists on digitalis\u2010induced ventricular arrhythmias","volume":"207","author":"Helke C","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_8_2","first-page":"193","article-title":"Physiology and pharmacology of vomiting","volume":"5","author":"Borison HC","year":"1953","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1977.tb03919.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.11.4230"},{"key":"e_1_2_1_11_2","first-page":"581","article-title":"Substrate specificity of brain hexokinase","volume":"210","author":"Scles A","year":"1954","journal-title":"J Biochem"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.901770302"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197612020-00001"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(79)90418-7"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(82)90589-1"},{"key":"e_1_2_1_16_2","first-page":"230","article-title":"Ouabain cardiotoxicity: A reassessment of methodology","volume":"224","author":"Cagin NA","year":"1976","journal-title":"Arch Int Pharmacdyn Ther"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(84)90032-3"},{"key":"e_1_2_1_18_2","first-page":"182","article-title":"The assay of strophanthus preparations by the cat method","volume":"7","author":"MacDonald AD","year":"1934","journal-title":"Q J Pharm Pharmacodyn"},{"key":"e_1_2_1_19_2","first-page":"161","article-title":"The use of the spinal cat for the estimation of the potency of cardiac glycosides","volume":"1","author":"Mendez R","year":"1942","journal-title":"Fed Proc"},{"key":"e_1_2_1_20_2","first-page":"97","article-title":"The modification of digitalis intoxication by excluding adrenergic influences on the heart","volume":"144","author":"Erlij D","year":"1964","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_21_2","first-page":"19","article-title":"The role of the nervous system in the cardiovacular effects of digitalis","volume":"31","author":"Gillis R","year":"1979","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.45.1.136"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI104113"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107883"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.49.1.226"},{"key":"e_1_2_1_26_2","first-page":"263","article-title":"Centrally mediated protective effects of dopamine agents on digitalis induced ventricular arrhythmias","volume":"207","author":"Helke GJ","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(78)90020-1"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.55.3.404"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F009127008502500709","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/009127008502500709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:20:16Z","timestamp":1697865616000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/009127008502500709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,10]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1985,10]]}},"alternative-id":["10.1177\/009127008502500709"],"URL":"https:\/\/doi.org\/10.1177\/009127008502500709","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,10]]}}}